{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Brandstetter LS"],"funding":["Julius-Maximilians-Universität Würzburg","Bavarian State Ministry for Health and Care"],"pagination":["125"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11756166"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["Background
The treatment of metastatic breast cancer (mBC) focuses on prolonging patient survival, providing adequate symptom management, and maintaining quality of life (QoL). This includes supportive therapy to prevent or treat potential side effects and handle comorbidities. The combination of mBC therapy, supportive therapy, and treatment for comorbidities increases the risk for polypharmacy, potential drug-drug interactions (pDDI), potentially inappropriate medication (PIM), and potentially missing drugs (pMD). Therefore, the aim of this study was to assess medication patterns of mBC patients in routine care within a cohort study from South Germany.Methods
Between July 2022 and February 2024 individuals with advanced or mBC, aged ≥ 18 years, living in Bavaria, and who "],"journal":["BMC cancer"],"pubmed_title":["Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study."],"pmcid":["PMC11756166"],"funding_grant_id":["PBN-MGP-2010-0004-DigiOnko"],"pubmed_authors":["Reese JP","Stork S","Heuschmann PU","Wockel A","Brandstetter LS","Salmen J","Grau A","Muller-Reiter M"],"additional_accession":[]},"is_claimable":false,"name":"Medication patterns and potentially inappropriate medication in patients with metastatic breast cancer: results of the BRE-BY-MED study.","description":"Background
The treatment of metastatic breast cancer (mBC) focuses on prolonging patient survival, providing adequate symptom management, and maintaining quality of life (QoL). This includes supportive therapy to prevent or treat potential side effects and handle comorbidities. The combination of mBC therapy, supportive therapy, and treatment for comorbidities increases the risk for polypharmacy, potential drug-drug interactions (pDDI), potentially inappropriate medication (PIM), and potentially missing drugs (pMD). Therefore, the aim of this study was to assess medication patterns of mBC patients in routine care within a cohort study from South Germany.Methods
Between July 2022 and February 2024 individuals with advanced or mBC, aged ≥ 18 years, living in Bavaria, and who ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-19T18:22:53.819Z","creation":"2025-04-19T18:22:53.819Z"},"accession":"S-EPMC11756166","cross_references":{"pubmed":["39844089"],"doi":["10.1186/s12885-025-13548-8"]}}